AstraZeneca encountered the most patent suits related to ‘Brilinta’
While a series of patent suits continues to be filed after the Patent-Linkage System is implemented, AstraZeneca was known to encounter the most number of patent challenges.
According to the analysis result of the Ministry of Food and Drug Safety’s pharmaceutical patent list, AstraZeneca has go...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
